QL-X-138 is a selective and potent BTK/MNK dual kinase inhibitor with IC50 of 8, 107.4, and 26 nM for BTK, MNK1, and MNK2, respectively.
QL-X-138 exhibits covalent binding to BTK and noncovalent binding to MNK.
QL-X-138 enhances the antiproliferative efficacies in vitro against a variety of B-cell cancer cell lines, as well as AML and CLL primary patient cells.
QL-X-138 arrests cell cycle progression and strongly induces apoptosis.
